Esperion Therapeutics, Inc. (ESPR)
| Market Cap | 765.35M |
| Revenue (ttm) | 227.55M |
| Net Income (ttm) | -143.55M |
| Shares Out | 27.47M |
| EPS (ttm) | -5.23 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | February 26 |
| Last Price | $27.39 |
| Previous Close | $27.68 |
| Change ($) | -0.29 |
| Change (%) | -1.05% |
| Day's Open | 27.89 |
| Day's Range | 26.23 - 28.24 |
| Day's Volume | 704,665 |
| 52-Week Range | 23.90 - 56.85 |
Esperion Therapeutics (ESPR) reports dismal fourth-quarter results as it misses estimates for earnings and sales. Sales were hurt due to COVID-19.
Esperion Therapeutics (ESPR) delivered earnings and revenue surprises of -3.46% and -49.17%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for...
Shares of Esperion Therapeutics (NASDAQ:ESPR) decreased after-market trading after the company reported Q4 results. Quarterly Results Earnings per share were down 72.12% over the past year to ...
ANN ARBOR, Mich., Feb. 23, 2021 (GLOBE NEWSWIRE) -- ESPERION (NASDAQ:ESPR), the lipid management company, today reported financial results for the fourth quarter and full year ended December 3...
ANN ARBOR, Mich., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), today announced it will report fourth quarter and full year 2020 financial results after the close of the U.S. fina...
Esperion is deeply undervalued company selling a new treatment in the huge and lucrative market for lowering LDL cholesterol. ESPR is highly leveraged to Covid-reopening, but unlike many indus...
ANN ARBOR, Mich., Jan. 29, 2021 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that, on January 28, 2021, the Compensation Committee of Esperion's Board of Directors granted 10 ne...
Esperion Therapeutics (NASDAQ: ESPR) shares are trading lower after Bank of America Securities downgraded the stock from Buy to Neutral and announced a price target of $35 per share. Esprit Ho...
Esperion (ESPR) reports fourth-quarter preliminary results and provides guidance for operating expense in 2021. The company in-licenses oral PCSK9 inhibitor program.
The company gave a sneak peek into its fourth-quarter financial results.
– Fourth-quarter 2020 U.S. net product revenue estimated between $8.0 and $8.5 million –
ANN ARBOR, Mich., Dec. 21, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), today announced that President and Chief Executive Officer, Tim M. Mayleben, will present at the virtual 39th Annua...
Esperion Therapeutics (NASDAQ: ESPR) shares are trading higher on Wednesday after the company announced Swiss Approval for the first-in-class cholesterol-lowering treatment NILEMDO and its Com...
- NILEMDO ® (bempedoic acid) is the first oral, once-daily treatment approved in almost two decades to lower low-density lipoprotein cholesterol (LDL-C) for indicated patients -
MUNICH & ANN ARBOR, Mich.--(BUSINESS WIRE)--Daiichi Sankyo Europe GmbH (hereafter, ‘Daiichi Sankyo') and Esperion Therapeutics (NASDAQ: ESPR) announced today Swissmedic approval for NILEMDO®▼ ...
ANN ARBOR, Mich., Dec. 15, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced the appointment of Sheldon Koenig, a proven leader in the cardiovascular market, as chief operating ...
Esperion Therapeutics (ESPR) reported earnings 30 days ago. What's next for the stock?
- Significant mean reduction of 26.5% in LDL-C with bempedoic acid vs. placebo in pooled analysis of people who cannot tolerate statins 1 -
ANN ARBOR, Mich., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced the pricing of $250.0 million aggregate principal amount of 4.00% Convertible Senior Subordinated No...
ANN ARBOR, Mich., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced its intention to offer, subject to market conditions and other factors, $200.0 million aggregate pri...
Esperion's approved product bempedoic acid is a non-statin, lipid-lowering drug with proven efficacy. However, high burn rate, poor uptake, and coronavirus have all dampened the prospects of t...
ANN ARBOR, Mich., Nov. 06, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that, on November 4, 2020, the Compensation Committee of Esperion's Board of Directors granted 33,66...
Esperion Therapeutics (ESPR) reports strong third-quarter results, beating estimates for earnings and sales. However, stock declines on COVID-19 related uncertainties.
Esperion Therapeutics, Inc. (ESPR) CEO Tim Mayleben on Q3 2020 Results - Earnings Call Transcript
Esperion Therapeutics (ESPR) delivered earnings and revenue surprises of 12.78% and 4.44%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for ...
Shares of Esperion Therapeutics (NASDAQ:ESPR) fell 2% in after-market trading after the company reported Q3 results. Quarterly Results Earnings per share fell 21.83% over the past year to ($3....
– Quarter-over-quarter Script Growth Exceeded 500 Percent for NEXLETOL ® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) tablets –
ANN ARBOR, Mich., Oct. 27, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), today announced that members of Esperion management will participate in three upcoming virtual conferences during t...
Esperion Therapeutics (ESPR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ANN ARBOR, Mich., Oct. 19, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), today announced it will report third quarter 2020 financial results after the close of the U.S. financial markets o...
ANN ARBOR, Mich., Sept. 28, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced the launch of “Break the Cycle with NEXLETOL”, a national direct-to-consumer (DTC) campaign aimed...
Esperion Therapeutics (ESPR) reported earnings 30 days ago. What's next for the stock?
ANN ARBOR, Mich., Sept. 02, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), today announced that members of Esperion management will participate in two upcoming virtual conferences during ...
ANN ARBOR, Mich., Aug. 26, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced that it will present a pooled analysis from four Phase 3 clinical trials of NEXLETOL® (bempedoic ac...
Sales of these recently launched products could make a big difference for the companies behind them.
Esperion Therapeutics (ESPR) reports mixed second-quarter results as it beats estimates for earnings and misses for sales.
Esperion Therapeutics, Inc. (ESPR) CEO Tim Mayleben on Q2 2020 Results - Earnings Call Transcript
Esperion Therapeutics (ESPR) delivered earnings and revenue surprises of 102.82% and -0.27%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the...
– Highest Quarterly and First Half Total Revenue in Company History with $214 million in Total YTD Revenue –
ANN ARBOR, Mich., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced it will report second quarter 2020 financial results after the close of the U.S. financial markets...
Esperion Therapeutics sees its Relative Strength Rating reach the 80-plus level. The post Esperion Therapeutics Scores Relative Strength Rating Upgrade; Hits Key Threshold appeared first on In...
ANN ARBOR, Mich., July 01, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that pooled efficacy analysis from the four Phase 3 clinical studies of NEXLETOL, an oral, once-da...
Esperion Therapeutics: An Easy Double, Maybe A Lot More
ANN ARBOR, Mich., June 22, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) announced the completion of an amendment to the EU commercial collaboration agreement with Daiichi Sankyo Europe (...
ANN ARBOR, Mich., June 14, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that pooled analysis from four Phase 3 clinical studies of NEXLETOL were presented at the American...
ANN ARBOR, Mich., June 12, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today confirms it has received notice that the Institute of Clinical and Economic Review (ICER) plans to assess ne...
ANN ARBOR, Mich., June 08, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that president and chief executive officer, Tim M. Mayleben, will participate in an analyst-led fi...
Esperion Therapeutics (ESPR) reported earnings 30 days ago. What's next for the stock?
Esperion Therapeutics (ESPR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
– First-Ever Non-Statin Combination Medicine, Providing 38 Percent Mean LDL-C Lowering – – Esperion Aims to Set New Industry Standard by Pricing NEXLIZET for Patient Affordability and Access ...
About ESPR
Esperion Therapeutics, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low-density lipoprotein cholesterol in the United States. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was founded in ... [Read more...]
| Industry Biotechnology | IPO Date Jun 26, 2013 |
| CEO Timothy Mayleben | Employees 479 |
| Stock Exchange NASDAQ | Ticker Symbol ESPR |
Financial Performance
In 2020, ESPR's revenue was $227.55 million, an increase of 53.37% compared to the previous year's $148.36 million. Losses were -$143.55 million, 47.7% more than in 2019.
Analyst Forecasts
According to 11 analysts, the average rating for ESPR stock is "Buy." The 12-month stock price forecast is 69.10, which is an increase of 152.28% from the latest price.